What happens to the eTMF after a clinical trial ends?

When a clinical trial closes, the relevance and importance of the electronic Trial Master File remains unchanged. What does change is how it should be managed.

During the study, the eTMF is a working environment used to collect, manage and review essential records. After study close, those records become a long-term regulatory asset. Sponsors still need to be able to demonstrate what happened during the trial, protect the integrity of the record and retrieve information if an inspector, auditor or internal team needs it years later.

That means study close is not simply the point at which the eTMF can be locked and forgotten. It is the point at which a new phase begins: controlled transfer, long-term retention, preservation and inspection-ready access.

So, what should happen to the eTMF once the trial is complete?

How the eTMF should be managed changes after study close

An operational eTMF is built around the needs of an active study: document collection, workflows, quality checks, completeness and collaboration. Once the trial has finished, many of those operational functions are no longer required, but the records themselves still need to be controlled for the full retention period.

This distinction matters because keeping a completed eTMF inside the same live platform is not automatically the same as archiving it for the long term. A retention strategy has to consider access, data integrity, readability, ownership, system lifecycle, cost and the risk that technology or suppliers will change over time.

The end-state should be simple: the sponsor knows exactly what has been retained, where it is held, who is responsible for it and how it can be produced when required.

1. Confirm the Trial Master File is complete before it is archived

The first step is to establish that the TMF is complete and ready to move out of its active-study phase. Archiving should not be used to hide unresolved completeness issues.

Before final transfer, sponsors should make sure outstanding records have been reconciled, expected documents are present, final quality activity is complete and any exceptions are documented. Where a CRO or third-party eTMF provider has managed the live system, the sponsor should also agree what constitutes the final transfer package and what evidence will accompany it.

This is one of the reasons close-out planning should begin well before the final study milestone. Waiting until access is being removed, suppliers are offboarding and study teams are dispersing makes missing information harder to resolve.

2. Agree ownership, responsibility and the transfer process

The sponsor needs clarity on who owns the retained records and who will be responsible for them during the archive period. That responsibility should not become ambiguous simply because the operational study team has moved on.

If the eTMF is being transferred from a CRO or eTMF provider, define the transfer method, the expected content, the accompanying metadata and the acceptance process in advance. The goal is not just to move files from one place to another. It is to preserve the context that makes those records understandable and defensible in the future.

Under the EU Clinical Trials Regulation, any transfer of ownership of the content of the clinical trial master file must be documented. Even outside the EU, clear ownership and chain of custody are fundamental controls for long-term records management.

3. Preserve the records, metadata and evidence that give the eTMF meaning

A usable eTMF is more than a folder of documents. Structure, metadata, audit information and relationships between records can all be important when someone needs to understand the history of a study later.

The archive process should therefore protect the information needed to demonstrate authenticity, integrity and context. Depending on the source system and the agreed archive scope, that may include document metadata, audit-trail information, indexes inventories and other supporting information required to interpret the retained records.

The exact transfer package should be agreed as part of the archive and validation plan rather than assumed at the point of export.

4. Move the completed eTMF into a fit-for-purpose long-term archive

Once the final TMF has been accepted, the sponsor needs a long-term home for it. This is where the requirements begin to differ from those of a live eTMF system.

A dedicated long-term archive should provide controlled retention, search and access while protecting the records against corruption, accidental loss and technology change. For digital records that may need to remain usable for decades, active preservation also matters: formats, software and infrastructure evolve, so the archive needs to manage the risk that today’s files become difficult to open or interpret in the future.

The objective is not simply to keep a copy. It is to retain an evidence base that remains findable, readable and trustworthy when it is eventually needed.

5. Retain the eTMF for the applicable period and keep it accessible

Retention periods depend on the regulatory framework and study context. In the EU, Article 58 of Regulation (EU) No 536/2014 (often referred to as EU CTR) requires the sponsor and investigator to archive the content of the clinical trial master file for at least 25 years after the end of the clinical trial, unless other Union law requires longer retention.

The same regulation requires the archived TMF to remain readily available and accessible to competent authorities, and the media used for archiving must allow the content to remain complete and legible throughout the retention period.

ICH E6(R3) also places emphasis on essential records remaining available, accessible and readable for the required retention period, with controls to prevent unauthorised access and accidental or premature destruction.

The practical point is important: retention is not just a date in a policy. It is an ongoing obligation to keep the record usable.

6. Protect long-term readability and data integrity

A 20- or 25-year retention period is long enough for file formats, applications, storage technologies, suppliers and internal teams to change several times. A record can still exist while becoming increasingly difficult to use.

Long-term eTMF archiving should therefore address both integrity and usability. Controls should help detect corruption or unexpected change, maintain an audit history, restrict access appropriately and support preservation activity when technology becomes obsolete.

This is where digital preservation goes beyond ordinary storage. The purpose is to keep the retained information understandable and usable over time, not simply present on a storage platform.

7. Decide what happens to the original eTMF platform

Once the archive transfer has been validated and accepted, sponsors can make a more informed decision about the future of the operational eTMF system. In some cases the platform may continue to support other live studies. In others, the organisation may want to reduce long-term dependency on a supplier or retire a system that is no longer required.

System retirement should be a controlled decision, not an automatic consequence of export. The sponsor needs confidence that the retained records, metadata and supporting evidence required for future access have been captured appropriately and that the archive can fulfil the organisation’s retention obligations.

When that work has been done properly, moving completed studies out of operational systems can also reduce unnecessary licence costs, simplify the application estate and avoid keeping legacy technology running purely for historical access.

8. Keep the archive inspection-ready throughout the retention period

Archiving is not a one-time close-out task. The records may need to be retrieved years after the study team has changed and the original system has disappeared.

The archive should make it straightforward to search for retained records, provide controlled access and demonstrate that governance has been maintained throughout the retention period. Responsibility for the archive should also remain clear when people leave, organisations restructure or ownership changes.

A useful test is to ask: if an inspector requested a specific set of trial records ten years from now, could the organisation find them, open them, understand them and demonstrate their integrity without rebuilding the original study environment?

What about the rest of the clinical trial data?

The eTMF is only one part of the information generated during a clinical trial. Once the study closes, sponsors may also need to retain data from EDC, eCRF, eCOA, ePRO, CTMS, IRT/RTSM, imaging platforms, statistical environments and other eClinical systems.

Managing each completed system as a separate long-term dependency can create data sprawl, inconsistent retention controls and growing cost. A consolidated clinical archive can provide a common long-term destination for the TMF alongside other retained clinical records and datasets, while allowing the organisation to manage retention and preservation more consistently.

A practical post-study eTMF checklist

• Confirm TMF completeness and document any final exceptions.
• Agree the archive scope and final transfer package with the CRO or eTMF provider.
• Define ownership and named responsibility for the retained archive.
• Retain the metadata, audit information and context needed to interpret the records.
• Validate transfer and acceptance into the long-term archive.
• Apply the correct retention period for the study and regulatory framework.
• Make sure records remain searchable, accessible and legible throughout retention.
• Protect the archive against corruption, unauthorised access and technology obsolescence.
• Only retire or reduce dependency on the original system after archive requirements are satisfied.
• Review the wider clinical data estate so the eTMF is not archived in isolation from other completed-study data.

How Arkivum supports post-study eTMF archiving

Arkivum provides a GxP-validated digital archiving and preservation solution designed for the long-term retention of regulated records and data. For completed eTMFs, Arkivum can provide the preservation layer after the live study system has finished its operational role.

Arkivum can work with sponsors, CROs and eClinical providers during migration, with quality and integrity checks forming part of the transfer process. Once retained, records can remain searchable and accessible through the archive while preservation and governance controls support long-term usability and inspection readiness.

For organisations looking beyond the TMF, Arkivum can also consolidate other completed-study records and datasets into a central clinical archive, helping reduce long-term system dependency and create a more consistent approach to retention.